Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Clot-Busting drug may help clear brain bleeds during surgery

NCT ID NCT05491356

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving a clot-busting drug called tPA directly into a chronic subdural hematoma (a slow brain bleed) helps drain it better during surgery. Forty adults who needed a twist-drill drainage procedure took part. The main goal was to see if the approach is feasible and safe, not yet to prove it works better than standard care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tissue plasminogen activator (tPA)
What this could lead to
If it works, this could lead to a better way to clear blood clots from the brain, possibly reducing the need for repeat surgeries.
What could go wrong
This is a small pilot study with only 40 people, so results may not apply widely. tPA also carries a risk of bleeding, especially in patients on blood thinners.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

May 2023

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adult patients (18 yrs or older) 2. Admitted to neurosurgery wing at the hospital 3. Symptomatic patients requiring surgical drainage by twist drill craniostomy Exclusion Criteria: 1. Patients at increased risk of bleeding such as patients taking anticoagulation medication that required reversal at time of intervention، or those with coagulopathic disorder. 2. Patients on antiplatelets or anticoagulation medications (DOACs or warfarin) with appropriate holding period prior to drainage, those who are eventually minimized to a regular bleeding risk compared to the normal population, will be included in the study. 3. Patients with subdural empyema. 4. Redo twist drill craniostomy for residual cSDH within the same admission. 5. Drain accidentally removed during nursing care or patient transport before 24 hr interval scan. 6. Patients who are not expected to live more than three months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibrinolytic; hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibrinolytic defect Hematoma, Subdural Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hamilton General Hospital

    Hamilton, Ontario, L8L 2X2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.